A new product will now provide U.S. veterinarians with an alternative to treat joint dysfunction in horses associated with equine osteoarthritis.
Keeping leg joints healthy in horses
NexHA is a purified hyaluronate sodium formulation approved by the Food and Drug Administration for the treatment of joint dysfunction in horses that is caused by non-infectious synovitis or osteoarthritis.
NexHA is a low molecular weight, purified hyaluronate sodium formulation that can be administered by I.V. or I.A. injection. It is approved by the Food and Drug Administration (FDA) for the treatment of joint dysfunction of the carpus or fetlock in horses that is caused by non-infectious synovitis or osteoarthritis.
“NexHA™ is an FDA-approved generic alternative to Legend®,” says Andrew Grant, President of Bioniche Animal Health (global). “This will allow veterinarians to provide more economical treatment options for equine joint disease due to synovitis or osteoarthritis.”
Hyaluronic Acid (HA) is a natural and essential component of articular cartilage and synovial fluid in horses. In joints affected by synovitis or osteoarthritis, the presence of HA is reduced.
NexHA is available in a 4ml (40 mg) vial for an intravenous injection. It is a clear, colorless, sterile, and preservative-free solution of low viscosity.
About Bioniche Animal Health:
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada and Athens, Georgia and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Armidale, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located. Visit www.bionicheanimalhealth.com.